ORCA Therapeutics is dedicated to significantly improving the lives of prostate cancer patients through the development of safe and highly potent oncolytic virus immunotherapies. Prostate cancer is the second leading cause of cancer death in men, and ORCA is committed to stopping it. The company's lead compound, ORCA 010, is currently in Phase I/IIa clinical testing in treatment-naive patients with localized prostate cancer. This study is being conducted in Canada and has received approval for the second dose level cohort in the dose escalation part.

ORCA Therapeutics operates in the biotechnology sector, focusing on innovative cancer treatments. The company primarily serves patients suffering from prostate cancer, aiming to provide them with more effective and safer treatment options. ORCA's business model revolves around the research, development, and clinical testing of its proprietary oncolytic virus therapies. The company generates revenue through partnerships, grants, and potentially future sales of its therapies upon successful clinical trials and regulatory approvals.

Keywords: oncolytic virus, prostate cancer, immunotherapy, clinical trials, biotechnology, cancer treatment, ORCA 010, Phase I/IIa, localized prostate cancer, innovative therapies.